Emily Peterson Alva net worth and biography

Emily Alva Biography and Net Worth

Director of Alkermes

Ms. Alva is an experienced financial, strategic and business advisor, with more than two decades of experience leading transactions and strategic evaluations for boards and leadership teams of large global companies and growth companies. She previously served as an M&A Partner at Lazard, a financial advisory and asset management firm, where she worked from 1997 to 2013. Ms. Alva is currently on the Boards of Directors of Amneal Pharmaceuticals, Inc., the Atlanta Life Insurance Company and the Mission Society of New York City. She is a corporate board partner with the Nasdaq Center for Board Excellence and a member of PathNorth, the NextGen Board Leaders, the EY Audit Committee Leaders and Extraordinary Women on Boards. Ms. Alva is also a faculty member and part of the founding leadership team of the Herndon Directors Institute, an innovative corporate governance initiative focused on the inclusion of business leaders from under-represented communities in corporate board rooms.

What is Emily Peterson Alva's net worth?: The estimated net worth of Emily Peterson Alva is at least $47,850.00 as of August 23rd, 2021. Ms. Alva owns 1,650 shares of Alkermes stock worth more than $47,850 as of November 7th. This net worth approximation does not reflect any other assets that Ms. Alva may own. Learn More about Emily Peterson Alva's net worth.
How do I contact Emily Peterson Alva?: The corporate mailing address for Ms. Alva and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Emily Peterson Alva's contact information.
Has Emily Peterson Alva been buying or selling shares of Alkermes?: Emily Peterson Alva has not been actively trading shares of Alkermes during the last quarter. Most recently, on Monday, August 23rd, Emily Peterson Alva bought 1,650 shares of Alkermes stock. The stock was acquired at an average cost of $30.22 per share, with a total value of $49,863.00. Following the completion of the transaction, the director now directly owns 1,650 shares of the company's stock, valued at $49,863. Learn More on Emily Peterson Alva's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 2 times. They sold a total of 20,888 shares worth more than $601,926.33. The most recent insider tranaction occured on November, 6th when EVP Craig C Hopkinson sold 10,471 shares worth more than $309,208.63. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 11/6/2024.

Emily Peterson Alva Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/23/2021	Buy	1,650	$30.22	$49,863.00	1,650

Emily Peterson Alva Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $29.00

$28.60

$29.21

50 Day Range

MA: $27.64

$25.70

$29.29

2 Week Range

Now: $29.00

$22.06

$32.88

Volume

879,001 shs

Average Volume

1,833,214 shs

Market Capitalization

$4.69 billion

P/E Ratio

14.87

Dividend Yield

N/A

Beta

0.47

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.